{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:49:54Z","timestamp":1792018194225,"version":"4.4.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["T32 DK062708"],"award-info":[{"award-number":["T32 DK062708"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001502","name":"Blue Cross Blue Shield of Michigan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001502","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009931","name":"Michigan Department of Health & Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009931","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000905","name":"The Commonwealth Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Biologic persistence, defined as the total uninterrupted time on a biologic agent, is associated with improved outcomes in inflammatory bowel disease (IBD). However, social determinants of health (SDOH), such as socioeconomic status, may influence a patient\u2019s ability to access these medications. We aimed to better understand the relationship between socioeconomic status and biologic persistence in patients with IBD and to determine whether patients with poor biologic persistence had higher health care utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified patients with IBD seen at the University of Michigan during 2015-2022. Using the Centers for Disease Control Social Vulnerability Index (SVI), we examined the relationship between socioeconomic status and biologic persistence, defined as an active biologic prescription for 365\u2009days or longer, while controlling a priori for IBD type, age, sex, race, comorbidities, IBD severity, and insurance type. Secondarily, we examined the relationship between biologic persistence and unplanned health care utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this cohort of 3067 patients with IBD who were prescribed biologics, 20% (n\u2009=\u2009620) did not achieve biologic persistence. Low socioeconomic status (odds ratio [OR] 0.56; P\u2009=\u2009.003) was associated with a lower likelihood of achieving biologic persistence. Biologic persistence was associated with lower risk of IBD-related hospitalization (incidence rate ratio [IRR], 0.48; P\u2009&amp;lt;\u2009.001), readmission (IRR, 0.52; P\u2009&amp;lt;\u2009.001), and surgery (IRR, 0.33; P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Low socioeconomic status was associated with lower likelihood of biologic persistence and patients who lacked biologic persistence had greater IBD-related unplanned health care utilization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag062","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:40:41Z","timestamp":1773924041000},"page":"1741-1749","source":"Crossref","is-referenced-by-count":1,"title":["Socioeconomic disparities in biologic persistence among patients with inflammatory bowel disease are associated with increased health care utilization"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-6575","authenticated-orcid":false,"given":"Jessica L","family":"Sheehan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dala","family":"Eloubeidi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Alabama Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira L","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel A","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5058-5527","authenticated-orcid":false,"given":"Shirley","family":"Cohen-Mekelburg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine , Ann Arbor, MI,","place":["United States"]},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan , Ann Arbor, MI,","place":["United States"]},{"name":"VA Center for Clinical Management Research, VA Ann Arbor Health Care System , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Berinstein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0610-9707","authenticated-orcid":false,"given":"Renuka","family":"Tipirneni","sequence":"additional","affiliation":[{"name":"Institute for Healthcare Policy and Innovation, University of Michigan , Ann Arbor, MI,","place":["United States"]},{"name":"Department of Internal Medicine, Michigan Medicine , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-4341","authenticated-orcid":false,"given":"Peter D R","family":"Higgins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"2026090114021746000_izag062-B1","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s Disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2026090114021746000_izag062-B2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"2026090114021746000_izag062-B3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026090114021746000_izag062-B4","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2026090114021746000_izag062-B5","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2026090114021746000_izag062-B6","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"2026090114021746000_izag062-B7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026090114021746000_izag062-B8","doi-asserted-by":"publisher","first-page":"e073071","DOI":"10.1136\/bmjopen-2023-073071","article-title":"Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocol","volume":"13","author":"Yiu","year":"2023","journal-title":"BMJ Open"},{"key":"2026090114021746000_izag062-B9","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/jcm14041357","article-title":"Temporal trends in the use of biological agents in patients with inflammatory bowel disease: real-world data from a tertiary Inflammatory Bowel Disease Greek Center during a 5-year period","volume":"14","author":"Markopoulos","year":"2025","journal-title":"J Clin Med"},{"key":"2026090114021746000_izag062-B10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/apt.16723","article-title":"Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases\u2014a Danish nationwide cohort study","volume":"55","author":"Zhao","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090114021746000_izag062-B11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.gastro.2024.01.041","article-title":"Early initiation of biologics and disease outcomes in adults and children with inflammatory bowel diseases: results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort","volume":"166","author":"Lujan","year":"2024","journal-title":"Gastroenterology"},{"key":"2026090114021746000_izag062-B12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026090114021746000_izag062-B13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.gastro.2020.08.064","article-title":"Effects of race and ethnicity on diagnosis and management of inflammatory bowel diseases","volume":"160","author":"Barnes","year":"2021","journal-title":"Gastroenterology"},{"key":"2026090114021746000_izag062-B14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/ibd\/izaa090","article-title":"Black and White patients with inflammatory bowel disease show similar biologic use patterns with Medicaid Insurance","volume":"27","author":"Barnes","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026090114021746000_izag062-B15","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.cgh.2020.05.056","article-title":"Prevalence and effects of food insecurity and social support on financial toxicity in and healthcare use by patients with inflammatory bowel diseases","volume":"19","author":"Nguyen","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026090114021746000_izag062-B16","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.14309\/ajg.0000000000000794","article-title":"Social determinants of outcomes in inflammatory bowel disease","volume":"115","author":"Bernstein","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2026090114021746000_izag062-B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izad034","article-title":"Residence in peripheral regions and low socioeconomic status are associated with worse outcomes of inflammatory bowel diseases: a nationwide study from the epi-IIRN","volume":"30","author":"Ledder","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026090114021746000_izag062-B18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/MEG.0000000000000899","article-title":"Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes","volume":"29","author":"Wardle","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026090114021746000_izag062-B19","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/ibd\/izz060","article-title":"Increased healthcare utilization by patients with inflammatory bowel disease covered by Medicaid at a tertiary care center","volume":"25","author":"Axelrad","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026090114021746000_izag062-B20","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00384-022-04180-0","article-title":"Effects of ethnicity and socioeconomic status on surgical outcomes from inflammatory bowel disease","volume":"37","author":"Stamatiou","year":"2022","journal-title":"Int J Colorectal Dis"},{"key":"2026090114021746000_izag062-B21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/apt.15107","article-title":"Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors","volume":"49","author":"Agrawal","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2026090114021746000_izag062-B22","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.cgh.2022.03.011","article-title":"The impact of the social determinants of health on disparities in inflammatory bowel disease","volume":"20","author":"Anyane-Yeboa","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090114021746000_izag062-B23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s10620-024-08733-x","article-title":"Disparities in vaccination amongst socially vulnerable patients with inflammatory bowel disease","volume":"70","author":"Sheehan","year":"2025","journal-title":"Dig Dis Sci"},{"key":"2026090114021746000_izag062-B24","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.2105\/AJPH.2022.307018","article-title":"Associations of 4 geographic social vulnerability indices with US COVID-19 incidence and mortality","volume":"112","author":"Tipirneni","year":"2022","journal-title":"Am J Public Health"},{"key":"2026090114021746000_izag062-B25","doi-asserted-by":"publisher","first-page":"e2036462","DOI":"10.1001\/jamanetworkopen.2020.36462","article-title":"Association of social and demographic factors with COVID-19 incidence and death rates in the US","volume":"4","author":"Karmakar","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026090114021746000_izag062-B26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jaccao.2022.06.005","article-title":"Impact of social vulnerability on comorbid cancer and cardiovascular disease mortality in the United States","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026090114021746000_izag062-B27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1123\/jpah.2015-0042","article-title":"Can the Social Vulnerability Index be used for more than emergency preparedness? An examination using youth physical fitness data","volume":"13","author":"Gay","year":"2016","journal-title":"J Phys Act Health"},{"key":"2026090114021746000_izag062-B28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jss.2019.05.022","article-title":"Using the Social Vulnerability Index to examine local disparities in emergent and elective cholecystectomy","volume":"243","author":"Carmichael","year":"2019","journal-title":"J Surg Res"},{"key":"2026090114021746000_izag062-B29","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1093\/ibd\/izad246","article-title":"Are depression and anxiety underdiagnosed in socially vulnerable patients with inflammatory bowel disease?","volume":"30","author":"Sheehan","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026090114021746000_izag062-B30","author":"CDC SVI Documentation 2018 | Place and Health | ATSDR","year":"2022"},{"key":"2026090114021746000_izag062-B31","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/ibd\/izaa263","article-title":"Development and validation of an inflammatory bowel disease severity index using US Administrative Claims Data: a retrospective cohort study","volume":"27","author":"Chen","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026090114021746000_izag062-B32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026090114021746000_izag062-B33","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.14309\/ajg.0000000000002851","article-title":"Insurer-mandated medication utilization barriers are associated with decreased insurance satisfaction and adverse clinical outcomes: an inflammatory bowel disease partners survey","volume":"119","author":"Constant","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026090114021746000_izag062-B34","doi-asserted-by":"publisher","first-page":"otae032","DOI":"10.1093\/crocol\/otae032","article-title":"Remote between visit monitoring in inflammatory bowel disease care: a qualitative study of CAPTURE-IBD participants and care team members","volume":"6","author":"Aintabi","year":"2024","journal-title":"Crohns Colitis 360"},{"key":"2026090114021746000_izag062-B35","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/apt.18006","article-title":"Meta-analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease","volume":"59","author":"Yiu","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090114021746000_izag062-B36","doi-asserted-by":"publisher","first-page":"otab076","DOI":"10.1093\/crocol\/otab076","article-title":"Persistence, dosing, and other treatment patterns among Crohn\u2019s disease patients initiating biologics in United States","volume":"3","author":"Teeple","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"2026090114021746000_izag062-B37","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1007\/s10620-020-06434-9","article-title":"Black race and public insurance are predictive of inappropriate evaluation of iron deficiency anemia and diarrhea","volume":"66","author":"Anyane-Yeboa","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2026090114021746000_izag062-B38","doi-asserted-by":"publisher","first-page":"g2979","DOI":"10.1136\/bmj.g2979","article-title":"Ecological studies: advantages and disadvantages","volume":"348","author":"Sedgwick","year":"2014","journal-title":"BMJ"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/9\/1741\/68160469\/izag062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/9\/1741\/68160469\/izag062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:02:22Z","timestamp":1788285742000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/9\/1741\/8662630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,4,25]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag062","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,4,25]]}}}